Tectonic Therapeutic, Inc.
NASDAQ:TECXBiotechnology
-$0.29 today
- Market cap
- $411.32M
- Beta
- 1.22
- P/E (TTM)
- -6.7
- EPS (TTM)
- -$4.45
Volume 0.17M
Average 0.20M
Returns on capital
Tectonic Therapeutic, Inc. management
Start with the returns management earns on the capital it controls, then review the people, their trades, and growth quality.
Return Metrics
ROE, ROIC & ROA over time
ROE
-29.5%
avg -67.4%
ROIC
-33.3%
avg -1422.1%
ROA
-28.4%
avg -73.8%
Analysis
ROA is currently the strongest return metric at -28.4% versus its period average of -73.8%. 0 of 3 return metrics are above their quality threshold, which helps indicate how efficiently the company turns capital and assets into profit.
Leadership
Who runs the company?
Review the executive team, tenure, compensation, and ownership.
Management
Key executives, compensation & ownership
| Name | Title | Compensation | Age | Shares Owned | Ownership % |
|---|---|---|---|---|---|
Alise S. Reicin | President, Chief Executive Officer, Secretary & Director | USD 1.03M | 65 | — | — |
Daniel Lochner | Chief Financial Officer | USD 728.71K | 44 | 58.02K | 0.31% |
Marcella K. Ruddy | Chief Medical Officer | USD 723.25K | 63 | 67.16K | 0.36% |
Mary West | Senior Vice President of Clinical Development Operations | — | — | — | — |
Marc Schwabish | Chief Business Officer | — | 46 | 44.90K | 0.24% |
John Diener | Senior Vice President of Antibody Engineering & Protein Sciences | — | — | — | — |
Anthony Muslin | Chief Development Officer | — | — | — | — |
Washington Alves | Senior Vice President of Technical Operations | — | — | — | — |
Geraldine Peters-Wiles | Senior Vice President of Human Resources | — | — | — | — |
Peter McNamara | Chief Scientific Officer | — | 54 | 54.30K | 0.29% |
Compensation is shown in the reported currency; data updated Nov 7, 2026.
Ownership uses each executive's latest SEC Form 4 holding only when the full name maps to one reporting CIK; latest matched holding Sep 30, 2026.
Insider trading
Are insiders buying or selling?
Follow recent insider purchases and sales reported on Form 4.
Insider Trading
SEC Form 4 transactions — last 12 months
Buys
3
$235,160.00
Sells
11
$651,006.74
Net Transaction Value
−$415,846.74
Net selling
Most Active
McNamara Peter
8 transactions
Transactions sorted by date, descending.
| Type | |||
|---|---|---|---|
| Sep 30, 26Sep 30, 2026 | McNamara Peter Direct | Sell | $12.3K$12,349.44 |
| Aug 25, 26Aug 25, 2026 | McNamara Peter Direct | Sell | $1.6K$1,570.36 |
| Aug 12, 26Aug 12, 2026 | McNamara Peter Direct | Sell | $1.5K$1,505.00 |
| Jun 30, 26Jun 30, 2026 | McNamara Peter Direct | Sell | $6K$6,020.00 |
| May 4, 26May 4, 2026 | Ruddy Marcella K. Direct | Sell | $32K$31,950.00 |
| Apr 1, 26Apr 1, 2026 | Ruddy Marcella K. Direct | Sell | $31.1K$31,050.00 |
| Mar 6, 26Mar 6, 2026 | McNamara Peter Direct | Sell | $181.4K$181,410.00 |
| Mar 6, 26Mar 6, 2026 | McNamara Peter Direct | Sell | $7.5K$7,525.00 |
| Mar 6, 26Mar 6, 2026 | Ruddy Marcella K. Direct | Sell | $300K$300,000.00 |
| Mar 4, 26Mar 4, 2026 | McNamara Peter Direct | Sell | $41.3K$41,250.00 |
1–10 of 14
Summary
Insiders reported 3 buys worth $235,160.00 and 11 sells worth $651,006.74 over the last 12 months. That adds up to net selling of $415,846.74. McNamara Peter was the most active insider with 8 transactions.
Growth analysis
Is management growing the business?
Compare historical growth with analyst forecasts across revenue, earnings, and cash flow.
Growth Analysis
Historical CAGR & forward analyst estimates
| Metric | 10yr | 5yr | 3yr | Fwd Est. |
|---|---|---|---|---|
| EPS | N/A | N/A | N/A | N/A6 analysts |
| Revenue | N/A | N/A | N/A | N/A6 analysts |
| Net Income | N/A | N/A | N/A | N/A6 analysts |
| EBIT | N/A | N/A | N/A | N/A6 analysts |
Analysis
Analysis will appear once historical growth or forward estimates are available for this company.
Competitors
Who does Tectonic Therapeutic, Inc. compete with?
Open similar companies to compare how their management teams allocate capital.
Competitors
Peer companies in the same sector
Questions
Management questions
Common questions about TECX's management, answered from reported figures.
Who manages TECX?
Tectonic Therapeutic, Inc. (TECX) lists 10 active executives. The top listed executive is Alise S. Reicin, President, Chief Executive Officer, Secretary & Director.
Are TECX insiders buying or selling?
Recent insider activity shows net buying of $90.55M.
Continue the stock analysis
Jump to another research area for this company.